

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this revised notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this revised notice.



吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8049)

REVISED NOTICE OF ANNUAL GENERAL MEETING

Reference is made to the notice of the annual general meeting (the “**Original Notice**”) of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the “**Company**”) dated 24 April 2026.

REVISED NOTICE IS HEREBY GIVEN that the annual general meeting (the “**AGM**”) of the Company will be held as originally scheduled at Economic Development Zone, Chaoyang Town, Huinan County, Jilin Province, the PRC on Tuesday, 9 June 2026 at 10:00 a.m. to consider and, if thought fit, pass the following resolutions (with or without amendments). Save for Ordinary Resolution No. 10, the other resolutions set out in the Original Notice remain unchanged.

ORDINARY RESOLUTIONS

1. to receive and consider the audited consolidated financial statements of the Company and the reports of the Directors of the Company and the independent auditor’s report of the Company for the year ended 31 December 2025;
2. to consider and approve the report of the Supervisory Committee of the Company for the year ended 31 December 2025;
3. to consider the reappointment of Prism Hong Kong Limited as auditors of the Company for the year ending 31 December 2026 and authorise the Directors to fix their remuneration;
4. to consider and approve the remuneration proposals for Directors and supervisors of the Company for the year ending 31 December 2026;

5. to re-elect the directors of the ninth session of the Board for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorise the Board to fix their remuneration (for details of the director candidates, please refer to Appendix I of the Original Notice):
 - (a) to re-elect Mr. Zhang Yi as an executive director;
 - (b) to re-elect Mr. Xu Xiang Fu as an executive director;
 - (c) to re-elect Mr. Gao Qi Pin as an independent non-executive director;
 - (d) to re-elect Mr. Bai Jun Gui as an independent non-executive director; and
 - (e) to re-elect Ms. Tian Jie as an independent non-executive director;
6. to re-elect the supervisors of the ninth session of the Supervisory Committee of the Company for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorise the Board to fix their remuneration:
 - (a) to re-elect Mr. Yan Li Yu as a supervisor; and
 - (b) to re-elect Mr. Wang Ying Xu as a supervisor;
7. to consider and approve the election and appointment of Mr. Wang Wei as an executive director of the Board for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorise the Board to fix his remuneration (for details of the director candidates, please refer to Appendix II of the Original Notice);
8. to consider and approve the election and appointment of Ms. Chi Chun Hong as an executive director of the Board for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorise the Board to fix her remuneration (for details of the director candidates, please refer to Appendix II of the Original Notice);
9. to consider and approve the election and appointment of Ms. Li Ning as an executive director of the Board for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorise the Board to fix her remuneration (for details of the director candidates, please refer to Appendix II of the Original Notice);

10. to consider and approve the election and appointment of Ms. Yang Yang as a supervisor of the Company for a term of three years commencing from 9 June 2026, until the date of the Annual General Meeting to be held in 2029, and to authorise the Board to fix her remuneration (for details of the supervisor candidates, please refer to the announcement of the Company dated 13 May 2026).

SPECIAL RESOLUTION

1. to consider and if the right fit, pass with or without modifications, the following resolution as a special resolution:

“**THAT:**

- (a) subject to paragraphs (c), (d) and (e) below, the exercise by the Board of Directors of the Company (the “**Board**”) during the Relevant Period (as defined in paragraph (f) below) of all the powers of the Company separately or concurrently to allot, issue and deal with domestic shares of nominal value of RMB0.10 each in the share capital of the Company (the “**Domestic Shares**”) and/or overseas-listed foreign shares of nominal value of RMB0.10 each in the share capital of the Company (the “**H Shares**”) be and is hereby approved;
- (b) the approval in paragraph (a) above shall authorise the Board to make an offer or agreement or grant an option during the Relevant Period which would or might require Domestic Shares and/or H Shares to be allotted and issued either during or after the end of the Relevant Period;
- (c) the aggregate nominal value of Domestic Shares to be allotted and issued or agreed to be allotted and issued (whether pursuant to an option or otherwise) by the Board pursuant to the approval in paragraphs (a) and (b) above, otherwise than pursuant to (i) a rights issue (as defined in paragraph (f) below); (ii) the exercise of the conversion rights under the terms of any securities which are convertible into such shares; (iii) the exercise of rights of subscription under the terms of any warrants issued by the Company; or (iv) any scrip dividend or similar arrangement providing for the allotment of such shares in lieu of the whole or part of a dividend on such shares in accordance with the articles of association of the Company, shall not exceed 20 per cent. of the aggregate nominal value of the Domestic Shares then in issue at the date of the passing of this resolution;

- (d) the aggregate nominal value of H Shares to be allotted and issued or agreed to be allotted and issued (whether pursuant to an option or otherwise) by the Board pursuant to the approval in paragraphs (a) and (b) above, otherwise than pursuant to (i) a rights issue (as defined in paragraph (f) below); (ii) the exercise of the conversion rights under the terms of any securities which are convertible into such shares; (iii) the exercise of rights of subscription under the terms of any warrants issued by the Company; or (iv) any scrip dividend or similar arrangement providing for the allotment of such shares in lieu of the whole or part of a dividend on such shares in accordance with the articles of association of the Company, shall not exceed 20 per cent. of the aggregate nominal value of the H Shares then in issue at the date of the passing of this resolution;
- (e) the approval in paragraph (a) above shall be conditional upon the approval of the China Securities Regulatory Commission being obtained by the Company;
- (f) for the purpose of this special resolution:

“Relevant Period” means the period from the passing of this special resolution until whichever is the earlier of:

- (i) the conclusion of the next annual general meeting of the Company following the passing of this special resolution;
- (ii) the expiration of a period of 12 months following the passing of this special resolution; or
- (iii) the date on which the authority set out in this special resolution is revoked or varied by a special resolution of the members of the Company in general meeting.

“Rights Issue” means an offer of shares open for a period fixed by the Directors to holders of shares of the Company on the register of members of the Company on a fixed record date and, where appropriate, the holders of the other equity securities of the Company entitled to be offered therein, in proportion to their then holdings of such shares or other equity securities (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of any relevant jurisdiction, or the requirements of any regulatory body or any stock exchange);

- (g) the Board be and is hereby authorised to make such amendments to the articles of association of the Company as it thinks fit so as to increase the registered share capital and to reflect the new capital structure of the Company as a result of the allotment and issue of shares of the Company pursuant to the approval granted under paragraph (a) above”.

2. to transact any other business.

By order of the Board
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
Zhang Hong
Chairman

Jilin, the PRC, 13 May 2026

Notes:

1. A revised form of proxy for use at the AGM (the “**Revised Proxy Form**”) is enclosed with this revised notice.
2. Any shareholder of the Company (the “**Shareholder**”) entitled to attend and vote at the AGM is entitled to appoint one or more proxies to attend and vote on his/her behalf. A proxy need not be a Shareholder.
3. If a Shareholder has not yet returned the original proxy form enclosed with the Original Notice (the “**Original Proxy Form**”) and intends to appoint a proxy to attend the AGM, he/she is required to complete and return the Revised Proxy Form. In such case, the Shareholder needs not return the Original Proxy Form.
4. If a Shareholder has already completed and returned the Original Proxy Form in accordance with the instructions printed thereon, please note that:
 - (a) If no Revised Proxy Form is returned to the Company, the Original Proxy Form (if correctly completed and returned) will be treated as a valid proxy form. The proxy so appointed will be entitled to vote at his/her discretion or abstain from voting on all resolutions properly put to the AGM, including the new Ordinary Resolution No. 10 set out above.
 - (b) If the Revised Proxy Form is returned not less than 24 hours before the time appointed for holding the AGM, the Revised Proxy Form will revoke and supersede the Original Proxy Form previously returned. The Revised Proxy Form (if correctly completed and returned) will be treated as a valid proxy form.
5. In order to be valid, the Revised Proxy Form, together with the power of attorney or other authority (if any) under which it is signed, must be deposited at the Company’s H share registrar, Computershare Hong Kong Investor Services Limited (for holders of H shares) or the Company’s registered address at 31 BEISHAN STREET, CHAOYANG TOWN, HUINAN COUNTY, TONGHUA, JILIN PROVINCE, THE PEOPLE’S REPUBLIC OF CHINA (for holders of domestic shares) not less than 24 hours before the time appointed for holding the AGM or any adjournment thereof.